Figure S6.

Phenotypic characterization of SARS-CoV-2-specific MBCs elicited by COVID-19 vaccines. Related to Figure 6

(A) Representative gating strategy of spike MBCs with a classical (CD21⁺CD27⁺), activated (CD21⁻CD27⁺) and atypical (CD21⁻CD27⁻) phenotype. Control gating on IgD⁺ B cells is shown for comparison.

(B-D) Freq. of (B) activated (CD21⁻CD27⁺), (C) classical (CD21⁺CD27⁺) and (D) atypical (CD21⁻ CD27⁻) spike MBCs at 3.5 months.

(E) CD71 expression by activated and classical spike-binding MBCs, at 3.5 months.

(F-G) Frequency of (F) CD71⁺ and (G) CXCR3⁺ spike-binding MBCs, at 6 months.

(H) Frequency of CD95⁺ cells among spike MBCs at 3.5 (left) and 6 (right) months.

(I) Frequency of CD11c⁺ cells among spike MBCs at 3.5 (left) and 6 (right) months.

(J) Frequency of Tbet⁺ cells among spike MBCs at 3.5 months.

(K-L) Frequency of CD11c⁺ or CD95⁺ cells among CXCR3⁺ or CXCR3^- spike MBCs at 3.5 months.

(M) Representative gating to evaluate co-expression of CXCR3 and CD95 or CD11c.

(N) Example of co-expression of CXCR3 and CD95 or CD11c in response to mRNA-1273 or Ad26.COV2.S vaccines.

Data were analyzed for statistical significance using Kruskal-Wallis (KW) test [(B), (C), (D), (E), (F), (G), (H), (I), (J), (K), (L)], Mann-Whitney test [(N)], Wilcoxon matched-pairs signed rank test [(E)]. Data are represented as mean ± SD.